OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

The accepted paper, titled "Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study", will be presented in the Ocular Surface ...
The Manila Times

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the ...
The Manila Times

OKYO Pharma Announces Successful Type C Meeting with the FDA

Key highlights from the Type C FDA meeting include: FDA confirms the approach that the proposed primary endpoint of the ...

OKYO Pharma LTD: FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

LONDON and NEW YORK, Jan. 23, 2026), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseas ...

Meet The Silver-Backed Chevrotain — A Mouse-Deer That Vanished For 25 Years, Rediscovered By A Camera Trap

Once written off as extinct, the silver-backed chevrotain forces scientists to confront how much of biodiversity still lives ...
Health.com

4 Benefits of Using Beetroot Powder for Your Health

Jillian Kubala, MS, is a registered dietitian based in Westhampton, NY. Jillian uses a unique and personalized approach to help her clients achieve optimal wellness through nutrition and lifestyle ...